EverQuote, Inc.
EVER Nasdaq Services-Computer Programming, Data Processing, Etc. Financials FY2017βFY2025
What EverQuote, Inc. does
No business description yet.
- Legal name
- EverQuote, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 24, 2026
- Accession Β· CIK
- 0001193125-26-066957
0001640428
Revenue and margins
EverQuote, Inc. had $693M of revenue in fiscal 2025, up 38.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $90.3M in fiscal 2025, 13.0% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
EverQuote, Inc. returned $21.0M to shareholders in fiscal 2025, 23% of free cash flow. The diluted share count rose 3.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably EverQuote, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $34.9M | $30.8M | $38.0M | $102M | $171M |
| Current ratio | 1.8x | 1.8x | 2.3x | 2.4x | 2.9x |
| Quick ratio | 1.8x | 1.8x | 2.3x | 2.4x | 2.9x |
| Total assets | $144M | $157M | $111M | $211M | $327M |
| Total liabilities | $58.5M | $49.0M | $30.0M | $75.2M | $88.9M |
| Shareholders' equity | $85.1M | $107M | $80.9M | $135M | $238M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 6 / 8 | 3 / 8 | 4 / 8 | 1 / 8 | 3 / 8 | 6 / 8 | 5 / 8 |
| Accruals ratio | β16.7% | β27.6% | β14.7% | β19.9% | β19.5% | β5.7% | β36.2% | β21.4% | 1.5% |
| Altman Z'' | β11.48 | β0.46 | 0.34 | 0.26 | β0.92 | β0.65 | β4.27 | 3.19 | 6.59 |
9 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $126M | $163M | $249M | $347M | $419M | $404M | $288M | $500M | $693M |
| Net interest income | β | $0.1M | $0.7M | $0.2M | $0.0M | β | β | β | β |
| Gross profit | $118M | $152M | $233M | $326M | $395M | $380M | $265M | $479M | $673M |
| Research and development | $9.2M | $14.2M | $20.2M | $29.7M | $35.7M | $31.7M | $27.6M | $29.6M | $31.5M |
| Operating income | β$4.7M | β$13.9M | β$8.0M | β$11.7M | β$21.9M | β$24.8M | β$52.0M | $31.8M | $58.3M |
| Interest expense | $0.4M | $0.2M | β | β | β | β | β | β | β |
| Pretax income | β | β | β$7.1M | β$11.2M | β$21.9M | β$24.4M | β$50.7M | $34.0M | $61.8M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | β$2.5M | β | $0.6M | $1.8M | β$37.5M |
| Net income | β$5.1M | β$13.8M | β$7.1M | β$11.2M | β$19.4M | β$24.4M | β$51.3M | $32.2M | $99.3M |
| Net income to common | β$19.2M | β$51.2M | β$7.1M | β | β | β | β | β | β |
| Diluted EPS | β$2.18 | β$3.03 | β$0.28 | β$0.41 | β$0.67 | β$0.77 | β$1.54 | $0.88 | $2.63 |
| Diluted shares | 0.01B | 0.02B | 0.00B | 0.00B | 0.00B | 0.00B | 0.03B | 0.04B | 0.04B |
| Cash flow | |||||||||
| Cash from operations | β$1.7M | β$1.9M | $4.4M | $10.7M | $7.2M | β$15.8M | β$2.8M | $66.6M | $95.4M |
| Capital expenditure | $1.2M | $3.7M | $3.0M | $3.8M | $2.9M | $4.3M | $3.8M | $4.1M | $5.1M |
| Free cash flow | β$2.9M | β$5.6M | $1.4M | $6.8M | $4.3M | β$20.1M | β$6.7M | $62.5M | $90.3M |
| Depreciation and amortization | $1.4M | $1.3M | $2.2M | $3.4M | $5.1M | $5.8M | $6.2M | $5.7M | $3.8M |
| Stock-based compensation | $1.9M | $7.1M | $12.7M | $24.2M | $30.0M | $29.0M | $24.1M | $20.6M | $24.3M |
| Share buybacks | $9.2M | β | β | β | β | β | β | β | $21.0M |
| Dividends and buybacks | $9.2M | β | β | β | β | β | β | β | $21.0M |
| Balance sheet | |||||||||
| Cash and short-term investments | $2.4M | $41.6M | $46.1M | $42.9M | $34.9M | $30.8M | $38.0M | $102M | $171M |
| Total debt | $4.6M | β | β | β | β | β | β | β | β |
| Current assets | $17.7M | $60.6M | $85.3M | $97.4M | $84.7M | $81.0M | $69.2M | $172M | $256M |
| Current liabilities | $15.0M | $21.4M | $38.4M | $46.8M | $47.4M | $45.4M | $29.9M | $72.6M | $87.2M |
| Property and equipment, net | $2.1M | $4.5M | $5.2M | $6.2M | $5.8M | $6.5M | $5.7M | $6.2M | $7.9M |
| Goodwill | β | β | β | $9.8M | $21.5M | $21.5M | $21.5M | $21.5M | $21.5M |
| Intangible assets | β | β | β | $3.4M | $10.2M | $8.0M | $5.2M | $3.3M | $0.0M |
| Total assets | $20.5M | $65.7M | $91.2M | $129M | $144M | $157M | $111M | $211M | $327M |
| Total liabilities | $20.1M | $22.6M | $39.5M | $58.1M | $58.5M | $49.0M | $30.0M | $75.2M | $88.9M |
| Shareholders' equity | β$50.5M | $43.2M | $51.8M | $71.0M | $85.1M | $107M | $80.9M | $135M | $238M |
| Margins | |||||||||
| Gross margin | 93.9% | 92.9% | 93.6% | 93.8% | 94.3% | 94.1% | 92.2% | 95.8% | 97.2% |
| Operating margin | β3.7% | β8.5% | β3.2% | β3.4% | β5.2% | β6.1% | β18.1% | 6.3% | 8.4% |
| EBITDA margin | β2.6% | β7.7% | β2.4% | β2.4% | β4.0% | β4.7% | β15.9% | 7.5% | 9.0% |
| Net margin | β4.0% | β8.4% | β2.9% | β3.2% | β4.6% | β6.0% | β17.8% | 6.4% | 14.3% |
| FCF margin | β2.3% | β3.4% | 0.6% | 2.0% | 1.0% | β5.0% | β2.3% | 12.5% | 13.0% |
| Net interest share of revenue | β | 0.1% | 0.3% | 0.1% | 0.0% | β | β | β | β |
| Returns | |||||||||
| Return on capital employed | β85.2% | β31.3% | β15.2% | β14.2% | β22.8% | β22.3% | β64.2% | 23.0% | 24.3% |
| Return on equity | β | β | β15.0% | β18.3% | β24.9% | β25.4% | β54.4% | 29.7% | 53.2% |
| Return on assets | β24.9% | β32.0% | β9.1% | β10.2% | β14.3% | β16.3% | β38.4% | 20.0% | 37.0% |
| Return on tangible equity | β | β118.6% | β13.7% | β19.4% | β36.4% | β31.3% | β94.6% | 29.1% | 45.9% |
| Growth | |||||||||
| Revenue growth | β | 29.4% | 52.3% | 39.4% | 20.6% | β3.4% | β28.8% | 73.7% | 38.5% |
| Net income growth | β | β | β | β | β | β | β | β | 208.7% |
| EPS growth | β | β | β | β | β | β | β | β | 198.9% |
| FCF growth | β | β | β | 376.1% | β36.8% | β564.1% | β | β | 44.6% |
| Share count change | β | 92.9% | β99.8% | 5.8% | 6.6% | 8.6% | 105,438.0% | 9.9% | 3.0% |
| Financial health | |||||||||
| Interest coverage | β12.3x | β69.9x | β | β | β | β | β | β | β |
| Current ratio | 1.2x | 2.8x | 2.2x | 2.1x | 1.8x | 1.8x | 2.3x | 2.4x | 2.9x |
| Quick ratio | 1.2x | 2.8x | 2.2x | 2.1x | 1.8x | 1.8x | 2.3x | 2.4x | 2.9x |
| Capital allocation | |||||||||
| Capex / revenue | 0.9% | 2.2% | 1.2% | 1.1% | 0.7% | 1.1% | 1.3% | 0.8% | 0.7% |
| Stock comp / revenue | 1.5% | 4.4% | 5.1% | 7.0% | 7.2% | 7.2% | 8.4% | 4.1% | 3.5% |
| Payouts / FCF | β | β | β | β | β | β | β | β | 23.3% |
| Quality scores | |||||||||
| Piotroski F-score | β | 3.0 | 6.0 | 3.0 | 4.0 | 1.0 | 3.0 | 6.0 | 5.0 |
| Altman Z'' | β11.5 | β0.5 | 0.3 | 0.3 | β0.9 | β0.6 | β4.3 | 3.2 | 6.6 |
| Accruals ratio | β16.7% | β27.6% | β14.7% | β19.9% | β19.5% | β5.7% | β36.2% | β21.4% | 1.5% |
Source: SEC EDGAR XBRL filings (CIK 0001640428). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.